about
Distinguishing between patients with pure psychogenic nonepileptic seizures and those with comorbid epilepsy by means of clinical data.Symptoms and course of intoxication with mesuximide--a case report.Topiramate overdose: a case report of a patient with extremely high topiramate serum concentrations and nonconvulsive status epilepticus.Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial.Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide.A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: The VITOBA study.Development of psychosis in patients with epilepsy treated with lamotrigine: report of six cases and review of the literature.The relevance of neuropsychiatric symptoms and cognitive problems in new-onset epilepsy - Current knowledge and understanding.BGG492 as an adjunctive treatment in patients with partial-onset seizures: A 12-week, randomized, double-blind, placebo-controlled, phase II dose-titration study with an open-label extension.Anxiety disorders in people with epilepsy.Health-related quality of life in double-blind Phase III studies of brivaracetam as adjunctive therapy of focal seizures: A pooled, post-hoc analysis.Ictal autoscopic phenomena and near death experiences: a study of five patients with ictal autoscopies.Epilepsy in the elderly: comparing clinical characteristics with younger patients.Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication.Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy.Informing patients about the impact of provocation methods increases the rate of psychogenic nonepileptic seizures during EEG recording.Unilateral autoscopic phenomena as a lateralizing sign in focal epilepsy.Epilepsy in the elderly: restrictions, fears, and quality of life.Validation of rapid suicidality screening in epilepsy using the NDDIE.A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures.My personal history with Epilepsy & behavior.Comparison of lacosamide concentrations in cerebrospinal fluid and serum in patients with epilepsy.Efficacy and safety of pregabalin in refractory focal epilepsy with and without comorbid anxiety disorders - results of an open-label, parallel group, investigator-initiated, proof-of-concept study.Dose-dependent suppression of human photoparoxysmal response with the competitive AMPA/kainate receptor antagonist BGG492: Clear PK/PD relationship.Out-of-body experience and epilepsy.Assessment of the correlations of lacosamide concentrations in saliva and serum in patients with epilepsy.Cognitive adverse events of topiramate in patients with epilepsy and intellectual disability.Serum concentrations of rufinamide in children and adults with epilepsy: the influence of dose, age, and comedication.Changes in hormone and lipid levels in male patients with focal seizures when switched from carbamazepine to lacosamide as adjunctive treatment to levetiracetam: A small phase IIIb, prospective, multicenter, open-label trial.Prevalence of anxiety disorders in patients with refractory focal epilepsy--a prospective clinic based survey.Consensus guidelines into the management of epilepsy in adults with an intellectual disability.Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures.Behavioral disorder in people with an intellectual disability and epilepsy: A report of the Intellectual Disability Task Force of the Neuropsychiatric Commission of ILAE.[Out-of-body experience as possible seizure symptom in a patient with a right parietal lesion].Everolimus dosing recommendations for tuberous sclerosis complex-associated refractory seizures.Adjunctive use of controlled-release pregabalin in adults with treatment-resistant partial seizures: A double-blind, randomized, placebo-controlled trialAcetazolamide in the Treatment of Acute Mania[Therapeutic drug monitoring in epileptology and psychiatry]Soluble Telencephalin in the serum of children after febrile seizuresFluctuation of lacosamide serum concentrations during the day and occurrence of adverse drug reactions--first clinical experience
P50
Q30814616-538FDA95-28EA-438D-91D7-943A627D0E21Q34289441-F88E8A11-6E2C-4F83-80A6-DDD58D30D7FEQ35011245-34F80FA3-7249-476B-B90D-AC7A9BA6DC92Q36052924-5E33A8DE-CA0F-4F97-8F51-CE2833446D44Q36351042-E43EC69E-177D-4691-AD4E-333267E57772Q36533062-87629259-D73B-4345-AA6A-8B33C8054E12Q36813574-959272F4-3645-4B19-BFA7-28D66607C39EQ38570190-B188E684-0237-45E4-A375-C4417D64AC9FQ38788365-E20DC382-4C42-41E7-85DA-C61E3F02E501Q38818106-E6ABF753-60C3-4045-A150-83BCEF2B1D06Q38942572-8CA97366-A481-4D0B-BFC5-D64A79F16FBDQ43961774-C1984D7C-10B7-4093-856A-58D1B23F5E54Q45022616-DDB6CDE7-20BD-499C-A79B-A922F733E9F0Q45237211-9A01EEBE-154F-4C89-8E52-24E8B8EA977FQ45286677-CBB27338-FBF3-4F96-A2A3-0BD2B760D334Q45847306-24C71EE4-325F-46F2-9374-45C5891C00A7Q46221188-13969695-530D-4BA9-94D5-6A9F9B774666Q47800010-4CD18958-6F57-4B25-B731-76C454F0CF01Q47874233-D214A3C5-52D9-4F03-8872-D55CBD88BA05Q47926989-BCC0D041-DA4B-47DA-AC73-98A9394B033FQ48058346-F34D6782-C4D2-42B0-9DC2-E3F0E81D991BQ48169987-6354798B-CDD4-4D85-ADC2-A0AF2507BDACQ48174091-0098AE93-30A9-4A8E-BFC3-5DAF355C3B49Q48188407-3DEDCAEE-9A37-4CFF-A298-813711291511Q48422518-D3A72354-A410-4F1B-905D-E406DAF9CD98Q49946090-F686891F-67F4-422B-BC5F-0EB4C2CAAE0BQ50593168-2F8B8B09-AD43-4C31-BAAD-4B53245465EBQ51595188-878FCC51-587A-4EF4-A1CE-219C5231985FQ51637918-928AA5FD-A05A-4BAD-8A2C-D9B75D5D941EQ51857625-88D12D64-F9A4-493A-BF37-3EB82CF6F84BQ51867616-1E5F6F93-3056-44D9-BA8C-30279C84A36FQ53204793-CC6428BE-14B8-4157-ADAD-368DED346A39Q53751766-2F2F1A97-85AC-4F47-9279-81A3A7C57AD9Q55471417-E6E8A052-65FB-4B49-8C06-DC0594C40F2AQ55602133-D77566B5-02BB-4210-A80C-36FCE3E7FAC6Q57544053-2CDA033E-1EC4-4885-8CF5-210992E7A211Q60646371-4454DBC7-E6BB-426E-B419-A525B598F319Q80801158-CEF4D7A1-269F-4907-A69A-34580E96463AQ81430013-D834692E-8696-4B1B-BCC2-39A530EC56CFQ84036587-78729017-E8C1-4BAB-9490-C16F8D4D182D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Christian Brandt
@ast
Christian Brandt
@en
Christian Brandt
@es
Christian Brandt
@fr
Christian Brandt
@nl
Christian Brandt
@sl
type
label
Christian Brandt
@ast
Christian Brandt
@en
Christian Brandt
@es
Christian Brandt
@fr
Christian Brandt
@nl
Christian Brandt
@sl
prefLabel
Christian Brandt
@ast
Christian Brandt
@en
Christian Brandt
@es
Christian Brandt
@fr
Christian Brandt
@nl
Christian Brandt
@sl
P1053
D-9217-2013
P106
P1153
55851947720
P21
P31
P3829
P496
0000-0001-8666-1640